Candriam SCA’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $94.6M | Buy |
314,512
+90,182
| +40% | +$27.2M | 0.43% | 47 |
|
|
2026
Q1 | $74.2M | Hold |
224,330
| – | – | 0.39% | 49 |
|
|
2025
Q4 | $89.2M | Buy |
224,330
+11,914
| +6% | +$5.27M | 0.44% | 46 |
|
|
2025
Q3 | $96.9M | Sell |
212,416
-25,668
| -11% | -$10.5M | 0.51% | 36 |
|
|
2025
Q2 | $77.6M | Sell |
238,084
-11,835
| -5% | -$3.27M | 0.45% | 47 |
|
|
2025
Q1 | $67.5M | Sell |
249,919
-32,488
| -12% | -$8.35M | 0.42% | 49 |
|
|
2024
Q4 | $66.5M | Sell |
282,407
-69,261
| -20% | -$18.2M | 0.38% | 60 |
|
|
2024
Q3 | $96.7M | Buy |
351,668
+440
| +0.1% | +$115K | 0.56% | 36 |
|
|
2024
Q2 | $85.3M | Buy |
351,228
+34,330
| +11% | +$5.42M | 0.52% | 39 |
|
|
2024
Q1 | $47.4M | Buy |
316,898
+66,514
| +27% | +$11.1M | 0.3% | 73 |
|
|
2023
Q4 | $47.9M | Sell |
250,384
-78,510
| -24% | -$13.4M | 0.33% | 75 |
|
|
2023
Q3 | $58.2M | Buy |
328,894
+10,000
| +3% | +$1.91M | 0.41% | 55 |
|
|
2023
Q2 | $60.6M | Sell |
318,894
-9,397
| -3% | -$1.86M | 0.44% | 54 |
|
|
2023
Q1 | $60.5M | Buy |
328,291
+7,796
| +2% | +$1.64M | 0.42% | 52 |
|
|
2022
Q4 | $76.2M | Sell |
320,495
-32,553
| -9% | -$6.94M | 0.51% | 36 |
|
|
2022
Q3 | $70.7M | Buy |
353,048
+9,835
| +3% | +$1.88M | 0.5% | 39 |
|
|
2022
Q2 | $50.1M | Buy |
343,213
+39,560
| +13% | +$5.61M | 0.41% | 60 |
|
|
2022
Q1 | $49.6M | Buy |
303,653
+63,082
| +26% | +$9.61M | 0.34% | 70 |
|
|
2021
Q4 | $40.8M | Buy |
240,571
+107,492
| +81% | +$20M | 0.26% | 99 |
|
|
2021
Q3 | $25.1M | Sell |
133,079
-41,743
| -24% | -$7.83M | 0.17% | 139 |
|
|
2021
Q2 | $29.6M | Buy |
174,822
+12,264
| +8% | +$1.8M | 0.2% | 118 |
|
|
2021
Q1 | $20.3M | Hold |
162,558
| – | – | 0.17% | 145 |
|
|
2020
Q4 | $21.1M | Sell |
162,558
-5,042
| -3% | -$673K | 0.17% | 146 |
|
|
2020
Q3 | $24.4M | Hold |
167,600
| – | – | 0.23% | 106 |
|
|
2020
Q2 | $24.8M | Sell |
167,600
-23,132
| -12% | -$3.12M | 0.26% | 99 |
|
|
2020
Q1 | $21.5M | Hold |
190,732
| – | – | 0.24% | 87 |
|
|
2019
Q4 | $22M | Buy |
190,732
+659
| +0.3% | +$65.7K | 0.24% | 87 |
|
|
2019
Q3 | $15.3M | Sell |
190,073
-191,651
| -50% | -$15.2M | 0.2% | 119 |
|
|
2019
Q2 | $27.6M | Buy |
381,724
+97,023
| +34% | +$7.44M | 0.34% | 58 |
|
|
2019
Q1 | $26.6M | Hold |
284,701
| – | – | 0.34% | 57 |
|
|
2018
Q4 | $20.8M | Buy |
284,701
+53,491
| +23% | +$4.11M | 0.32% | 62 |
|
|
2018
Q3 | $20.2M | Buy |
231,210
+112,500
| +95% | +$11.3M | 0.27% | 85 |
|
|
2018
Q2 | $11.7M | Buy |
118,710
+23,500
| +25% | +$2.33M | 0.19% | 142 |
|
|
2018
Q1 | $11.3M | Buy |
95,210
+102
| +0.1% | +$13.2K | 0.19% | 138 |
|
|
2017
Q4 | $12.1M | Sell |
95,108
-24,892
| -21% | -$3.13M | 0.21% | 133 |
|
|
2017
Q3 | $14.1M | Buy |
120,000
+36,000
| +43% | +$3.07M | 0.25% | 108 |
|
|
2017
Q2 | $6.7M | Buy |
84,000
+17,000
| +25% | +$1.09M | 0.13% | 195 |
|
|
2017
Q1 | $3.43M | Buy |
67,000
+7,000
| +12% | +$324K | 0.07% | 335 |
|
|
2016
Q4 | $2.25M | Hold |
60,000
| – | – | 0.05% | 350 |
|
|
2016
Q3 | $4.07M | Sell |
60,000
-13,000
| -18% | -$917K | 0.1% | 225 |
|
|
2016
Q2 | $4.05M | Buy |
73,000
+12,000
| +20% | +$756K | 0.11% | 214 |
|
|
2016
Q1 | $3.81M | Buy |
61,000
+4,000
| +7% | +$266K | 0.1% | 233 |
|
|
2015
Q4 | $5.37M | Sell |
57,000
-5,400
| -9% | -$501K | 0.14% | 161 |
|
|
2015
Q3 | $5.01M | Sell |
62,400
-26,600
| -30% | -$2.96M | 0.12% | 205 |
|
|
2015
Q2 | $10.7M | Buy |
89,000
+62,000
| +230% | +$7.41M | 0.22% | 131 |
|
|
2015
Q1 | $2.82M | Sell |
27,000
-6,000
| -18% | -$608K | 0.06% | 346 |
|
|
2014
Q4 | $3.2M | Buy |
+33,000
| New | +$3.06M | 0.07% | 299 |
|
Other funds holding ALNY
Candriam SCA's ALNY Position: Q2 2026 in Review
Candriam SCA increased its Alnylam Pharmaceuticals (ALNY) stake by 40% in Q2 2026, buying an estimated $27.2M and bringing the position to 314,512 shares worth $94.6M. The position accounts for 0.43% of the portfolio, ranked #47.
Candriam SCA first reported a position in ALNY in Q4 2014 and has held it in 47 quarters since. The position peaked at $96.9M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Candriam SCA held 314,512 shares of Alnylam Pharmaceuticals worth $94.6M as of Q2 2026.
- Candriam SCA bought 90,182 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $27.2M.
- Alnylam Pharmaceuticals made up 0.43% of Candriam SCA's portfolio in Q2 2026, its #47 holding.
- Candriam SCA first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
- Candriam SCA's Alnylam Pharmaceuticals position peaked at $96.9M in Q3 2025.
- 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.